1. Lantheus faces investigation over alleged federal securities violations. 2. Q2 2025 results missed expectations, impacting revenue projections. 3. Share price plummeted by approximately 51.87% following the announcement. 4. CEO cited pricing pressure and strategic decisions as influencing factors. 5. Investors are encouraged to share information regarding the investigation.
The significant drop in share price reflects investor concerns over earnings guidance and legal scrutiny. Historical instances, like the 2020 stock crash in biopharma, show these issues lead to long-term distrust.
The article addresses critical financial performance and potential legal risks, directly influencing investor sentiment and stock performance.
Legal investigations can take months or years to resolve, maintaining uncertainty around Lantheus' stock. Past examples, such as Valeant Pharmaceuticals, faced prolonged negative impact from similar issues.
The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH) investors concerning the Company's possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On August 6, 2025, Lantheus announced disappointing second quarter 2025 results, revealing earnings-per-share ("EPS") and revenue figures that missed expectations. In addition, the Company lowered its full year 2025 revenue guidance from $1.550 billion - $1.585 billion to $1.475 billion - $1.51 billion and its full year 2025 adjusted fully diluted EPS guidance from $6.60 - $6.70 per share to $5.50 - $5.70 per share. During an earnings call held that same day, Lantheus's Chief Executive Officer cited intensified pricing pressure in the PSMA PET market and a conscious decision to walk away from volume at certain accounts to protect long-term franchise value. In addition, the Company's Chief Financial Officer stated that "[c]onsolidated net revenue for the second quarter was $378 million, a decrease of 4.1%."
On this news, the price of Lantheus shares declined by $20.76 per share, or approximately 51.87%, from $72.63 per share on August 5, 2025 to close at $51.87 on August 6, 2025.
What to Do Next?
If you acquired Lantheus securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests with respect to these matters without any cost to you.
Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909818795/en/
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com